Locoregional IL-2 low dose applications for gastrointestinal tumors

Table 1 Patients’ characteristics. A. Once weekly local IL-2 application. B. Once monthly local IL-2 application

No.	Sex	Primary tumor	Metastases	Neoplastic ascites	Route and dose of IL-2 application	Necrosis induction
W1	M	Pancreatic Ca	Liver, abdominal lymph nodes	-	1.5 MIU i.p.	-
W2	F	Stomach Ca	Liver, abdominal lymph nodes	-	4.5 MIU i.p.	-
W3	F	Colorectal Ca	Liver, lung	-	4.5 MIU i.p.+i.t.	Yes
W4	F	Colorectal Ca	Liver, abdominal lymph nodes	-	4.5 MIU i.t.	Yes
W5	M	Colorectal Ca	Peritoneum	+	1.5 MIU i.p.+i.t.	-
W6	F	Ovarian Ca	Lung, peritoneum, spleen	+	4.5 MIU i.t.	-
W7	F	Mammary Ca	Liver, lung, peritoneum	+	4.5 MIU i.p.	-
W8	M	Hemangiosarcoma	Liver, peritoneum, abdominal lymph nodes	+pleural effusion	4.5 MIU i.p.+i.t.	-
No.	Sex	Primary tumor	Metastases	Neoplastic ascites	Route of IL-2 application	Necrosis induction
M1	M	HCC, liver cirrhosis		-	4.5/9 MIU i.t.	-
M2	M	HCC, liver cirrhosis		-	4.5 MIU i.t.	Yes
M3	M	Abdominal mesothelioma	Peritoneum	-	9 MIU i.t.+i.p.	-
M4	F	Colorectal Ca	Liver	-	9 MIU i.t.	Yes
M5	F	Mammary Ca	Liver, bone, skin	–	1.5 MIU i.t.	-
M6	F	Mammary Ca	Liver	-	4.5/9 MIU i.t.	-
M7	M	HCC, liver cirrhosis		-	4.5 MIU i.t.	Yes

Ca, carcinoma; HCC, hepatocellular carcinoma; i.p., intraperitoneal; i.t., intratumoral; W, weekly IL-2 application; M, monthly IL-2 application.